Cargando…
Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo
Bone remodeling is a process delicately balanced between osteoclastic bone resorption and osteoblastic bone formation. Osteoclasts (OCs) are multinucleated giant cells formed through the fusion of monocytic precursors of the hematopoietic stem cells lineage. OCs are the exclusive cells responsible f...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737473/ https://www.ncbi.nlm.nih.gov/pubmed/33354217 http://dx.doi.org/10.1155/2020/8829212 |
_version_ | 1783622948808032256 |
---|---|
author | Li, Yu-Xi Chen, Fu-Chao Liu, Ting Cai, Zhao-Peng Chen, Keng Tang, Guo-Xue Huang, Jun-Shen Liu, Xiang-Ge Huang, Jia-Jun Wang, Peng Liang, Yu-Wei Huang, Lin |
author_facet | Li, Yu-Xi Chen, Fu-Chao Liu, Ting Cai, Zhao-Peng Chen, Keng Tang, Guo-Xue Huang, Jun-Shen Liu, Xiang-Ge Huang, Jia-Jun Wang, Peng Liang, Yu-Wei Huang, Lin |
author_sort | Li, Yu-Xi |
collection | PubMed |
description | Bone remodeling is a process delicately balanced between osteoclastic bone resorption and osteoblastic bone formation. Osteoclasts (OCs) are multinucleated giant cells formed through the fusion of monocytic precursors of the hematopoietic stem cells lineage. OCs are the exclusive cells responsible for the resorption and degradation of the mineralized bone matrix. Pantoprazole (PPZ), a proton pump inhibitor (PPI), is commonly prescribed to reduce excess gastric acid production for conditions such as gastroesophageal reflux disease and peptic ulcer disease. Studies have found contradictory effects of PPI therapy on bone metabolism due to the lack of understanding of the exact underlying mechanism. In this study, we found that PPZ inhibits receptor activator of nuclear factor-κB (NF-κB) ligand- (RANKL-) induced osteoclastogenesis from bone marrow monocytic/macrophage (BMMs) precursors and the bone-resorbing activity of mature OCs. Correspondingly, the expression of OC marker genes was also attenuated. At the molecular level, PPZ treatment was associated with reduced activation of the ERK MAPK signaling pathways crucial to OC differentiation. Additionally, the in vivo administration of PPZ protected mice against lipopolysaccharide- (LPS-) induced inflammatory calvarial bone erosion, as a result of the reduced number and activity of OCs on the calvarial bone surface. Although PPI use is associated with increased risk of osteoporosis and bone fractures, our study provides evidence for the direct inhibitory effect of PPZ on OC formation and bone resorption in vitro and in vivo, suggesting a potential therapeutic use of PPZ in the treatment of osteolytic disease with localized bone destruction. |
format | Online Article Text |
id | pubmed-7737473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-77374732020-12-21 Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo Li, Yu-Xi Chen, Fu-Chao Liu, Ting Cai, Zhao-Peng Chen, Keng Tang, Guo-Xue Huang, Jun-Shen Liu, Xiang-Ge Huang, Jia-Jun Wang, Peng Liang, Yu-Wei Huang, Lin Stem Cells Int Research Article Bone remodeling is a process delicately balanced between osteoclastic bone resorption and osteoblastic bone formation. Osteoclasts (OCs) are multinucleated giant cells formed through the fusion of monocytic precursors of the hematopoietic stem cells lineage. OCs are the exclusive cells responsible for the resorption and degradation of the mineralized bone matrix. Pantoprazole (PPZ), a proton pump inhibitor (PPI), is commonly prescribed to reduce excess gastric acid production for conditions such as gastroesophageal reflux disease and peptic ulcer disease. Studies have found contradictory effects of PPI therapy on bone metabolism due to the lack of understanding of the exact underlying mechanism. In this study, we found that PPZ inhibits receptor activator of nuclear factor-κB (NF-κB) ligand- (RANKL-) induced osteoclastogenesis from bone marrow monocytic/macrophage (BMMs) precursors and the bone-resorbing activity of mature OCs. Correspondingly, the expression of OC marker genes was also attenuated. At the molecular level, PPZ treatment was associated with reduced activation of the ERK MAPK signaling pathways crucial to OC differentiation. Additionally, the in vivo administration of PPZ protected mice against lipopolysaccharide- (LPS-) induced inflammatory calvarial bone erosion, as a result of the reduced number and activity of OCs on the calvarial bone surface. Although PPI use is associated with increased risk of osteoporosis and bone fractures, our study provides evidence for the direct inhibitory effect of PPZ on OC formation and bone resorption in vitro and in vivo, suggesting a potential therapeutic use of PPZ in the treatment of osteolytic disease with localized bone destruction. Hindawi 2020-11-28 /pmc/articles/PMC7737473/ /pubmed/33354217 http://dx.doi.org/10.1155/2020/8829212 Text en Copyright © 2020 Yu-Xi Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Yu-Xi Chen, Fu-Chao Liu, Ting Cai, Zhao-Peng Chen, Keng Tang, Guo-Xue Huang, Jun-Shen Liu, Xiang-Ge Huang, Jia-Jun Wang, Peng Liang, Yu-Wei Huang, Lin Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo |
title | Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo |
title_full | Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo |
title_fullStr | Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo |
title_full_unstemmed | Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo |
title_short | Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo |
title_sort | pantoprazole (ppz) inhibits rankl-induced osteoclast formation and function in vitro and prevents lipopolysaccharide- (lps-) induced inflammatory calvarial bone loss in vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737473/ https://www.ncbi.nlm.nih.gov/pubmed/33354217 http://dx.doi.org/10.1155/2020/8829212 |
work_keys_str_mv | AT liyuxi pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT chenfuchao pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT liuting pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT caizhaopeng pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT chenkeng pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT tangguoxue pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT huangjunshen pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT liuxiangge pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT huangjiajun pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT wangpeng pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT liangyuwei pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo AT huanglin pantoprazoleppzinhibitsranklinducedosteoclastformationandfunctioninvitroandpreventslipopolysaccharidelpsinducedinflammatorycalvarialbonelossinvivo |